OR WAIT null SECS
July 27, 2023
Roche will pay up to $2.8 billion for the rights to Alnylam’s RNA-based hypertension therapeutic.
July 24, 2023
Sanofi and Recludix Pharma’s deal centers on developing treatments for various immunological and inflammatory diseases.
July 21, 2023
Under a global license agreement, Bristol Myers Squibb and Evotec will advance the development of neurodegeneration pipeline assets.
The proposed spin-off of Sandoz into an independent entity has been approved by Novartis’ board of directors.
The partnership will see Flagship and Pfizer work to create a new pipeline of innovative medicines.
The expanded deal, now potentially worth more than $1.2 billion, will work to develop in vivo therapies, including sickle cell disease.
July 20, 2023
Novartis’ acquisition of biotech company DTx Pharma boosts its neuroscience pipeline and expands its capabilities in RNA-based therapeutics.
July 07, 2023
Camena Bioscience has completed $10 million in Series A financing on the back of growing demand for DNA synthesis.
July 06, 2023
Chime Biologics, Leads Biolabs, and BeiGene have formed a three-way collaboration to advance the development and global manufacturing of Leads Biolabs’ lead mAb candidate, LBL-007.
Meletios Therapeutics has been awarded with funding worth €1.2 million (US$1.3 million) from Bpifrance’s Deeptech development program.